This concept gained attention with two pivotal studies in 2009, published in the Journal of Clinical Oncology, which demonstrated the utility of AFP response, using thresholds of 50% and 20%, as a marker post-locoregional and systemic chemotherapy for HCC, respectively. Here, AFP is linked to hepatocellular carcinoma.